RT Book, Section
A1 Miller, David Michael
A1 Reddy, Bobby Y.
A1 Tsao, Hensin
A2 Kang, Sewon
A2 Amagai, Masayuki
A2 Bruckner, Anna L.
A2 Enk, Alexander H.
A2 Margolis, David J.
A2 McMichael, Amy J.
A2 Orringer, Jeffrey S.
SR Print(0)
ID 1161345477
T1 Molecular Targeted Therapies
T2 Fitzpatrick's Dermatology, 9e
YR 2019
FD 2019
PB McGraw-Hill Education
PP New York, NY
SN 9780071837798
LK accessmedicine.mhmedical.com/content.aspx?aid=1161345477
RD 2024/04/23
AB The  treatment  strategy  for  human  disease  has  evolved  dramatically  since  2000  as  a  result  of  advances  in  molecular  genetics,  cell  biology,  and  pharmacology.  Increased  understanding  of  molecular  pathophysiology  has  allowed  for  the  development  of  therapeutics  that  interact  with  specific  molecular  targets  associated  with  disease.  Agents  that  are  the  product  of  rational  drug  design,  in  which  compounds  are  deliberately  designed  to  interact  with  a  biologic  target,  are  often  referred  to  as  “targeted  therapy”  and  form  one  of  the  cornerstones  of  “precision  medicine.”  The  potential  of  targeted  therapy  is  perhaps  best  exemplified  with  oncologic  disease,  but  the  promise  of  rational  drug  design  is  beginning  to  be  seen  across  all  fields  of  medicine.